Table 2.

Clinical and pathologic data for individuals harboring TRIO gene fusion

CaseHistotypeGradeLocationMetastasisLocal recurrenceGenreChimeric transcriptsChromosome gene 1Chromosome gene 2Break position gene 1Break position gene 2ORF conservationNew aa before stop codon
T1UPS3Trunk wallYNFTRIO(ex33)-TERT(ex2)55144067811294781Y
TRIO(ex33)-TERT(ex3)55144067811282739N24
S867DD LPS3Lower limbNNMTRIO(ex33)-TERT(ex2)55144067811294781Y
TRIO(ex33)-TERT(ex3)55144067811282739N24
T2DD LPS2ExtremitiesNNMTRIO(ex34)-TERT(ex2)55144201301294781N117
TRIO(ex34)-TERT(ex3)55144201301282739Y
S829PRMS3Lower limbYYMTRIO(ex34)-TERT(ex2)55144201301294781N117
TRIO(ex34)-TERT(ex3)55144201301282739Y
S822UPS3Upper limbNYMTRIO(ex34)-CDH18(ex2)-TERT(ex2)55144201301294781N7
TRIO(ex34)-CDH18(ex2)-TERT(ex3)55144201301282739N7
S909UPS3Internal trunkYNFTRIO(ex33)-LINC01504(intron2)591440678174939905N37
TRIO(ex33)-LINC01504(intron3)591440678174948537N28
TRIO(ex33)-LINC01504(exon4)591440678174950306N98
S921MFS2Lower limbNNFTRIO(ex34)-ZNF558519144201308932224N196
  • Abbreviations: aa: amino acid; DDLPS, dedifferentiated liposarcoma; F, female; M, male; MFS, myxofibrosarcoma; N, no; PRMS, pleomorphic rhabdomyosarcoma; UPS, undifferentiated pleomorphic sarcoma; Y, yes.